As filed with the Securities and Exchange Commission on May 13, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Adagio Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
Delaware |
|
85-1403134 |
(State or other jurisdiction of
incorporation or organization) |
|
(I.R.S. Employer
Identification No.) |
1601 Trapelo Road, Suite 178
Waltham, MA 02451
(Address of principal executive offices) (Zip code)
2021 Equity Incentive Plan
(Full title of the plan)
David Hering
Interim
Chief Executive Officer and Chief Operating Officer
Adagio Therapeutics, Inc.
1601 Trapelo Road, Suite 178
Waltham, MA 02451
(Name
and address of agent for service)
(781) 819-0080
(Telephone number, including area code, of agent for service)
Copies to:
Jill
Andersen
Chief Legal Officer
Adagio Therapeutics, Inc.
1601 Trapelo Road, Suite 178
Waltham, MA 02451
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated
filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐